Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove

9% Disease Free After Phase II Study

Executive Summary

GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.

You may also be interested in...



GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.

AstraZeneca/Daiichi Sankyo’s Next ADC Shows Promise In Triple-Negative Breast Cancer

Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.

Avrobio Plots Comeback With Early Data From Gaucher’s Gene Therapy

Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel